加载中
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
前收盘价
US$2.12
−US$0.01 · -0.47%
盘后
US$2.14
+US$0.02 · +0.94%
10月12日 16:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
日内区间
当前US$2.12
52周区间
当前US$2.12
盘中时间采用ET。市场数据可能有所延迟。
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
日内区间
当前US$2.12
52周区间
当前US$2.12
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 297.64万 USD | 250.03万 USD | 254万 USD | 170.69万 USD | 116.07万 USD |
| 毛利 | 297.64万 USD | 250.03万 USD | 254万 USD | 170.69万 USD | 116.07万 USD |
| 研究与开发 | 306.55万 USD | 328.83万 USD | 349.48万 USD | 477.08万 USD | 316.35万 USD |
| 销售、一般及管理费用 | 274.55万 USD | 341.64万 USD | 356.09万 USD | 365.4万 USD | 374.4万 USD |
| 营业费用 | 581.1万 USD | 670.47万 USD | 705.57万 USD | 842.48万 USD | 690.75万 USD |
| 利息收入 | 14.8万 USD | 24.99万 USD | 35.58万 USD | 16.72万 USD | 10.05万 USD |
| 折旧和摊销 | — | 15.33万 USD | — | 2.7万 USD | 3.55万 USD |
| 营业利润 | −283.46万 USD | −420.44万 USD | −451.57万 USD | −671.79万 USD | −574.68万 USD |
| 净利润 | −268.09万 USD | −396.03万 USD | −413.46万 USD | −655.24万 USD | −564.52万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年5月15日 | 1:10 | — | — |
股票拆分 | 2019年6月25日 | 1:12 | — | — |
股票拆分 | 2016年6月6日 | 1:33 | — | — |
已生效 2023年5月15日
1:10
已生效 2019年6月25日
1:12
已生效 2016年6月6日
1:33
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
